ProtoKinetix Stock

ProtoKinetix Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of ProtoKinetix (PKTX) as of Aug 8, 2026 is -0.02. In the previous year, Net Debt to Free Cash Flow Ratio was 0.05 — a change of -135.63% (lower).

Net Debt/FCF

-0.02

YoY

-135.63%

Last updated:

Net Debt to Free Cash Flow Ratio of ProtoKinetix is 2026 -0.02 . Net Debt to Free Cash Flow Ratio of ProtoKinetix was 2025 0.05 . It decreases by -135.63% lower compared to the previous year.
Access this data via the Eulerpool API

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Net Debt to Free Cash Flow Ratio of ProtoKinetix is -0.02 in 2026.

Net Debt to Free Cash Flow Ratio of ProtoKinetix changed from 0.05 to -0.02, representing a -135.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — ProtoKinetix

All Key Metrics — ProtoKinetix